Gene:
FANCC
Fanconi anemia, complementation group C

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  FACC
Alternate Symbols:  FA3; FAC
PharmGKB Accession Id: PA27997

Details

Cytogenetic Location: chr9 : q22.32 - q22.32
GP mRNA Boundary: chr9 : 97861336 - 98079991
GP Gene Boundary: chr9 : 97858336 - 98089991
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. BARD1 signaling events - (Pathway Interaction Database NCI-Nature Curated)
  2. brca1 dependent ub ligase activity - (BioCarta via Pathway Interaction Database)
  3. role of brca1 brca2 and atr in cancer susceptibility - (BioCarta via Pathway Interaction Database)

LinkOuts

Entrez Gene:
2176
OMIM:
227645
UCSC Genome Browser:
NM_000136
RefSeq RNA:
NM_000136
RefSeq Protein:
NP_000127
RefSeq DNA:
AC_000052
AC_000141
NC_000009
NG_011707
NT_008470
NW_001839235
NW_924506
UniProtKB:
FANCC_HUMAN (Q00597)
Ensembl:
ENSG00000158169
GenAtlas:
FANCC
GeneCard:
FANCC
MutDB:
FANCC
ALFRED:
LO012810M
HuGE:
FANCC
Comparative Toxicogenomics Database:
2176
ModBase:
Q00597
HumanCyc Gene:
HS08272
HGNC:
3584

Common Searches